Background. The purpose of the present study was to assess the inhibitory effect of DuP 753, an orally active angiotensin II receptor antagonist, on the pressor action of exogenous angiotensin I and II in healthy male volunteers.
Methods and Results. In the first study (single-dose study), eight volunteers were included in a 2-day protocol repeated four times at 1-week intervals. In each phase, a different dose of drug (2.5, 5, 10, 20, or 40 mg) or placebo was given. The peak systolic blood pressure response to a test-dose of angiotensin I was determined serially before and after oral administration of DuP 753 by continuously monitoring finger blood pressure using a photoplethysmographic method. DuP 753 reduced the systolic blood pressure response to angiotensin I in a dose-dependent fashion. Three, 6, and 13 hours after the 40-mg dose, blood pressure response decreased to 31±5%, 37±6%, and 45+±3% of the control values (mean±SEM, n=7), respectively. In the second study, 29 volunteers were treated for 8 days with either a placebo or DuP 753 (5, 10, 20, or 40 mg p.o. q.d.) and challenged on the first, fourth, and eighth days with bolus injections of angiotensin II. Again, the inhibitory effect on the systolic blood pressure response to angiotensin II was clearly dose dependent. Six hours after 40 mg DuP 753, the systolic blood pressure response to the test-dose of angiotensin II was reduced to 37+7%, 40±4%, and 38±6% of baseline values (mean+SEM, n=6) on days 1, 4, and 8, respectively. With this latter dose, there was still a blocking effect detectable 24 hours after the drug. Similar to angiotensin converting enzyme and renin inhibitors, DuP 753 induced a dose-dependent increase in plasma renin that was more pronounced on the eighth than on the first day of drug administration. In these normal volunteers, no consistant clinically significant side effects were observed. There was no evidence for an agonist effect.
Conclusions. DuP 753 appears to be a well-tolerated, orally active, potent, and long-lasting antagonist of angiotensin II in men. (Circulation 1991; 83:1333 -1342 After elucidation of the different steps in the renin-angiotensin cascade, blockade of angiotensin II (Ang II) receptors was thought to represent a logical approach to inhibition Subsequently, drugs were developed that were intended to reduce circulating Ang JJ.5 Today, the angiotensin converting enzyme (ACE) inhibitors are widely used to treat hypertension and congestive heart failure.6-10 Many compounds are available that are both very effective and usually well tolerated. However, some class-specific side effects as cough, a quite frequent problem, and angioneurotic edema, a more serious but rare disorder, are encountered.1" It appears not unreasonable to relate these side effects to the lack of specificity of ACE inhibitors, which not only block the conversion of Ang I to Ang II but also reduce the degradation of bradykinin and substance P, two peptides capable of triggering cough.12 For this reason, the more specific enzyme renin has recently become the target for inhibition, 13 '19 The purpose of the present study was to assess for the first time the pharmacokinetic and pharmacodynamic profiles of DuP 753 after single and repeated oral administrations to normal human subjects. The results of this evaluation suggest that DuP 753 is a potent and long-acting antagonist of Ang II, not only in animals but also in humans.
Methods

Subjects
A total of 37 male subjects were recruited to carry out the two consecutive studies.
The first study involved eight volunteers 21-27 years old (mean age, 24 years) and weighing 61-83 kg (mean weight, 73 kg). The second study involved 29 volunteers 20-38 years old (mean age, 25 years) and weighing 53-87 kg (mean weight 70 kg). All subjects were considered healthy on the basis of a medical history, a physical examination, routine blood and urine analyses, and an electrocardiogram. The study protocols were approved by the institutional ethics committee. The nature, purpose, and potential risks of the study were explained to each volunteer, and written consent was required for entry into the study.
Blood Pressure Measurement
In both studies, to quantitate the pressor effect of exogenous angiotensin, blood pressure was measured at the finger using a photoplethysmograph (Finapres, Ohmeda, Englewood, Colo.). The measurement technique is based on the principle of the unloaded artery wall and was first described by Penaz in 1973.20 This noninvasive method measures finger arterial blood pressure continuously through a cuff wrapped around a finger. The monitor gives a beat-to-beat value of blood pressure (systolic, diastolic, and mean) and heart rate. Shortly before and during the 15 minutes after injection of each test-dose of angiotensin, the pressure waves and heart rate were continuously recorded on graduated paper. The peak blood pressure changes were calculated using these tracings.
Study Outline
Throughout the study, the volunteers were allowed to continue their usual free sodium intake. They were asked to come to our research facility at 7:00 AM on the first day of the study after an overnight fast. They were immediately placed in supine position, and venous catheters were inserted in a vein in each forearm. One line was used for angiotensin injections, and the other for blood sampling. The blood pressure-monitoring cuff was wrapped around the third or fourth finger on the side used for blood sampling. In the first study, plasma aldosterone, norepinephrine, and immunoreactive Ang II were measured before and 1/2, 2, 4, 7, and 23 hours after drug intake. During the second study, plasma renin activity (PRA) was determined with the same parameters on days 1, 4, and 8 before and 6 hours after dosing. In both studies, blood samplings were always performed immediately before the following angiotensin challenge. Aldosterone was determined by a direct radioimmunoassay.22 For 
Plasma Drug Levels
Plasma levels of DuP 753 were determined by a high-performance liquid chromatography method. Briefly, plasma standards or samples spiked with an internal standard, 1 ml H20, 0.3 ml of 0.1N KOH, and 0.25 ml of 10 mM tetrabutylammonium hydrogen sulfate were extracted with 8 ml methylene chloride. An aliquot of the organic phase was evaporated under a stream of nitrogen, the residue was reconstituted with 0.2 ml of mobile phase, and an aliquot (0.1 ml) was analyzed using a Zorbax R C-8 4.6 mmx25 cm column (E.I. du Pont de Nemours). Detection was accomplished using an ABI 783A ultraviolet detector (Applied Biosystems, Foster City, Calif.) set at 254 nm. The coefficient of variation of the in-study quality control plasma sample (9.9-183.2 ng/ml) ranged from 4.4% to 9.9%. The accuracy (found concentration divided by spiked concentration) The values of blood pressure and heart rate before and after (peak values) Ang I challenge are summarized in Table 1 . The changes in systolic blood pressure induced by the test-dose of Ang I were calculated as the differences between postchallenge and prechallenge values for each volunteer at each dose and at each time. Compared with placebo, no clear effect was observed with the doses of 2.5 and 5 mg. However, doses of 10, 20, and 40 mg induced a dose-dependent inhibition of the response to Ang I. Figure 1 shows the dose-related inhibition of the response to Ang I expressed in percent of the baseline response. The peak inhibitory effect was reached 7, 5, and 3 hours after intake of the 10-, 20-, and 40-mg doses of DuP 753, respectively. After a dose of 20 mg DuP 753, the blood pressure response to Ang I was decreased to 50%, whereas after the 40-mg dose it decreased to a level of 31%. An attenuation of the blood pressure response to Ang I was still present 24 hours after intake of the 20-and 40-mg doses. exogenous Ang II immediately before the morning dose of the drug (Table 2 and Figure 2 ). (10, 20 , and 40 mg). Then, the drug concentrations decreased progressively and became undetectable between hours S and 13 after drug intake. The drug half-life was estimated for all subjects as between 1.5 and 3.3 hours (2.1+0.6 hours, mean±SD). Figure 6 depicts the time courses of the drug levels and the corresponding inhibitions of the systolic blood pressure responses to Ang I (upper panel). In the lower panel of this figure, the time course of the drug levels is given with the plasma Ang II concentrations measured after administration of the single doses of DuP 753 (20 and 40 mg). There was a pronounced shift in time between the peak drug level and the peak inhibitory effect reflected by either inhibition of the Ang I pressure response or the compensatory increase in plasma Ang II levels. Furthermore, the inhibition of the response to Ang I as well as the increase in plasma Ang II were still present when the drug became undetectable in plasma. When the individual plasma drug levels were related to the concomitant plasma Ang II or the reduction in the Ang I-induced pressure response, there was no detectable correlation. Discussion It has recently become possible to characterize compounds such as ACE and renin inhibitors with progressively increasing degrees of accuracy by quantitating their effects on plasma ACE activity28 and, more important, on circulating levels of Ang I and/or Ang 11.29 The determination of true angiotensin-(1-8)-octapeptide is probably the best index by which to assess blockade of the renin-angiotensin enzymatic cascade.30 In contrast, the only practical way to estimate the effect of an Ang II receptor antagonist in a clinical setting is to monitor its inhibitory effect on the blood pressure response to exogenous Ang I or II. Until recently, a direct measurement of intraarterial blood pressure was necessary for the detection of the rapid blood pressure increase induced by the bolus injection of a pressor substance such as Ang I or II. However, intra-arterial catheterization involves a certain risk. Consequently, this approach was limited to studies of very small numbers of subjects, lasting for not more than a few hours. The recent development of a servophotoplethysmograph able to monitor blood pressure at the finger continuously i 1 a and noninvasively33 made the present study possible, which we could not have carried out a few years ago. In a pilot study performed in six normal subjects, the reproducibility of the systolic pressure response to repeated administration of an Ang I test-dose was evaluated over a period of 24 hours, and the mean coefficient of variation was found to be 15±2.4% (mean±SEM; range, 11-24%).31 Furthermore, the administration of captopril at doses of 6.25 and 25 mg p.o. reduced the response to Ang I in a pattern that confirmed the results obtained almost 15 years ago with intra-arterial blood pressure monitoring.32 Based on these preliminary results and on similar experiences reported recently by others,33,34 it was decided that the photoplethysmographic blood pressure method could be used to assess the efficacy of DuP 753 in iniormal volunteers.
The presenit data demonstrate that DuP 753 is a potent, orally active Ang II antagonist with a relatively long duration of action. At peak effect, the 40-mg dose induced an approximately 70% reduction in the systolic pressure response to Ang I or II. In addition, witlh this highest dose, even 24 hours after drug intake, ( definite blocking effect was still present. Notwithstanding, with repeated administration, no cumulativc progressive enhancement of the blocking effect 6 hours after drug could be observed. The dose-response relation that was observed with the blocking effect of the angiotensin-induced pressure response was also clearly reflected in the compensatory increase in PRA and immunoreactive Ang II.
Although 1'he different effects induced by the administration of the Ang II antagonist were clearly long lasting, the actual drug levels in plasma had relatively short half-lives varying between 1.5 and 3.3 hours in the individual subjects. Furthermore, there was no corrclation between the individual plasma drug levels acnd the concomitant plasma Ang IL or blockade of the Ang I-induced blood pressure response. These data quite strongly suggest that DuP 753 in its intact form is not the major active component responsible for the inhibitory action and that possibly some active metabolite exists in man. In animal experiments, metabolism of DuP 753 has been demonstrated, and an active metabolite has been identified. 35 It is thus probable that in humans, as in animals, DuP 753 is metabolized and that the main inhibitory action is exerted by one or more active metabolites.
PRA and Ang II levels responded with dosedependent compensatory increases as might have been expected based on earlier observations made with saralasin,2 the analogue of Ang II used as an Ang II antagonist, as well as on the extensive experience accumulated with ACE inhibitors. Not only was this compensatory increase dose dependent, but there also was a clear time factor (i.e., on day 8 of drug administration, the compensatory increase was clearly more pronounced than on day 1). This also is in agreement with findings obtained after administration of ACE inhibitors. 36 The long duration of the blocking effect of DuP 753 is also reflected in the PRA and Ang II levels. Thus, although on day 1 all predrug measurements provided similar results, on day 8, PRA as well as plasma Ang II were clearly increased before the administration of 20 or 40 mg compared with the predrug results obtained before placebo. Thus, 24 hours after the administration of 20 or 40 mg, there was still a significant compensatory increase in PRA and Ang II present. An important question is, of course, whether this compensatory increase in plasma Ang II levels can modify the inhibitory effect of the DuP 753. At the outset of the study, it was hoped that by measuring circulating Ang II and plasma drug levels while simultaneously evaluating the drug effect on the pressure response to Ang IL, it would be possible to assess the influence of the increasing Ang IL levels. Unfortunately, this was not possible because the measured drug levels do not appear to represent the main inhibitory compound.
No clear effect of the Ang II antagonist on plasma aldosterone could be detected. Had there not been a Even if a full dose-response curve to DuP 753 in humans were available, the comparison with a converting enzyme inhibitor would still be difficult. Although we have learned over the years that true Ang II levels have to be reduced markedly to obtain a good antihypertensive effect, we presently have little idea what percentage of Ang receptors on the smooth muscle cells of the arterioles have to be occupied by an Ang II antagonist to obtain a partial or maximal antihypertensive effect. The Ang II bolus doses used for testing in the present study induced, for a short period of time, much higher Ang II levels than are usually present at the angiotensin receptor site. Accordingly, even though the 40-mg dose of DuP 753 appears to provide only partial blockade of the pressure response to exogenous Ang I or II, it might represent a full or even excessive antihypertensive dose. Only when data become available from hypertensive patients studied under well-controlled conditions will it be possible to extrapolate from the degree of blockade measured in normal volunteers the doses necessary for a full antihypertensive effect in hypertensive patients.
Based on these preliminary data obtained in normal volunteers, it is not possible to predict the antihypertensive potency and efficacy of DuP 753. Nevertheless, the findings obtained with DuP 753 in hypertensive animals and the earlier observations made with saralasin suggest that DuP 753 will probably become an effective compound to treat hypertension and possibly congestive heart failure. Compared with ACE inhibitors, it would have the advantage of greater specificity. It shares with the ACE inhibitors as well as with the renin inhibitors the inescapable fact that the closed regulatory loop of renin secretion is fully operative; as a consequence, blockade at any point beyond the renin-secreting process automatically induces compensatory increases in renin and Ang II. Whether this compensatory increase has any clinical consequences remains to be seen.
